These inhibitors (PLX7904, and PLX8394), dubbed “paradox breakers”, have been shown to inhibit MAPK/ERK signaling in melanoma cells with BRAF mutations, without further inducing the pathway in cells bearing upstream activation. This evidence concerns the gene BRAF and melanoma.